Franklin Genomic Advancements ETF (HELX)

Assets	$10.54M
Expense Ratio	0.50%
PE Ratio	31.14
Shares Out	400,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	-18.69%

Volume	37,202
Open	26.30
Previous Close	26.49
Day's Range	25.90 - 26.30
52-Week Low	23.74
52-Week High	33.98
Beta	1.11
Holdings	70
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

39.17% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	6.15%
Vertex Pharmaceuticals Incorporated	VRTX	4.68%
Samsung Biologics Co.,Ltd.	207940	4.32%
Krystal Biotech, Inc.	KRYS	3.88%
Medpace Holdings, Inc.	MEDP	3.62%
Us Dollar	n/a	3.41%
Regeneron Pharmaceuticals, Inc.	REGN	3.38%
Eli Lilly and Company	LLY	3.29%
Corteva, Inc.	CTVA	3.23%
United Therapeutics Corporation	UTHR	3.21%